| First Author | Marin-Valencia I | Year | 2024 |
| Journal | Cell Metab | Volume | 36 |
| Issue | 6 | Pages | 1394-1410.e12 |
| PubMed ID | 38838644 | Mgi Jnum | J:349817 |
| Mgi Id | MGI:7658708 | Doi | 10.1016/j.cmet.2024.05.002 |
| Citation | Marin-Valencia I, et al. (2024) Imaging brain glucose metabolism in vivo reveals propionate as a major anaplerotic substrate in pyruvate dehydrogenase deficiency. Cell Metab 36(6):1394-1410.e12 |
| abstractText | A vexing problem in mitochondrial medicine is our limited capacity to evaluate the extent of brain disease in vivo. This limitation has hindered our understanding of the mechanisms that underlie the imaging phenotype in the brain of patients with mitochondrial diseases and our capacity to identify new biomarkers and therapeutic targets. Using comprehensive imaging, we analyzed the metabolic network that drives the brain structural and metabolic features of a mouse model of pyruvate dehydrogenase deficiency (PDHD). As the disease progressed in this animal, in vivo brain glucose uptake and glycolysis increased. Propionate served as a major anaplerotic substrate, predominantly metabolized by glial cells. A combination of propionate and a ketogenic diet extended lifespan, improved neuropathology, and ameliorated motor deficits in these animals. Together, intermediary metabolism is quite distinct in the PDHD brain-it plays a key role in the imaging phenotype, and it may uncover new treatments for this condition. |
